Accord Healthcare Italia Srl.

Accord Healthcare Italia Srl, established in 2008, is a subsidiary of Accord Healthcare, a global pharmaceutical company specializing in generic medicines, biosimilars, and specialty pharmaceuticals. Headquartered in Milan, Italy, at Viale Monza 265, the company operates within the wholesale distribution sector, focusing on the import and distribution of finished pharmaceutical formulations. Accord Healthcare Italia Srl plays a significant role in Italy's pharmaceutical supply chain, providing a broad range of generic medicines to healthcare professionals and patients across the country.

While specific details about Accord Healthcare Italia Srl's warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Milan suggests a centralized distribution model. This location facilitates efficient access to major transportation hubs, ensuring timely delivery of pharmaceutical products throughout Italy. The company's extensive product portfolio, including oncology, immunosuppressants, central nervous system (CNS) drugs, and cardiovascular and diabetes medications, indicates a well-established distribution network capable of meeting diverse healthcare needs.

Accord Healthcare Italia Srl functions primarily as a pharmaceutical importer and wholesaler within Italy's supply chain. By sourcing finished pharmaceutical formulations from international manufacturers, including a significant volume from India, the company ensures a steady supply of generic medicines to the Italian market. This role is crucial in enhancing the availability and affordability of essential medications, particularly in therapeutic areas such as oncology, immunology, and cardiovascular health.

Accord Healthcare Italia Srl's sourcing strategy exhibits a high degree of concentration, with a total import value of $1.4 million USD from India across 73 shipments, primarily from a single supplier, Intas Pharmaceuticals Limited. This single-source dependency may pose risks related to supply chain disruptions, pricing fluctuations, and regulatory changes affecting the supplier. However, the consistent volume of imports and the company's established relationship with Intas Pharmaceuticals Limited suggest a stable and reliable partnership. To mitigate potential risks, it would be prudent for Accord Healthcare Italia Srl to diversify its supplier base and explore alternative sources for critical products.

The resilience of Accord Healthcare Italia Srl's supply chain is closely tied to its reliance on Intas Pharmaceuticals Limited for a substantial portion of its imports. While this partnership offers stability, it also exposes the company to risks associated with geopolitical events, regulatory changes, and supply chain disruptions in India. To enhance supply chain resilience, Accord Healthcare Italia Srl could consider establishing relationships with additional suppliers, diversifying its product formulations, and developing contingency plans to address potential disruptions. Ensuring that all suppliers adhere to recognized Good Manufacturing Practice (GMP) standards is essential for maintaining product quality and regulatory compliance.

Accord Healthcare Italia Srl's concentrated sourcing strategy positions it as a significant player in the Italian pharmaceutical market, particularly in the oncology and immunology sectors. For Indian exporters, this presents an opportunity to strengthen partnerships with Accord Healthcare Italia Srl by offering a diverse range of high-quality generic medicines that meet the company's standards and regulatory requirements. By aligning with Accord Healthcare Italia Srl's strategic focus and addressing any supply chain vulnerabilities, Indian exporters can enhance their market presence and contribute to the company's growth in Italy.

In Italy, the Italian Medicines Agency (AIFA) serves as the primary regulatory authority overseeing the import and distribution of pharmaceutical products. The regulatory framework governing pharmaceutical imports includes the Ministerial Decree of 11 May 2001, which outlines procedures for importing medicines in case of shortages, and Legislative Decree 219/2006, which addresses the importation of parallel-imported drugs. These regulations ensure that imported medicines meet the necessary quality, safety, and efficacy standards before entering the Italian market. (aifa.gov.it)

Import licensing requirements for pharmaceutical products in Italy are stringent, necessitating that all imported medicines possess marketing authorization in the country of origin and comply with EU Good Manufacturing Practice (GMP) standards. The AIFA evaluates import requests based on these criteria to ensure that imported medicines are safe and effective for the Italian population. Additionally, wholesale distribution authorization is required for entities involved in the import and distribution of pharmaceutical products within Italy. (aifa.gov.it)

Imported pharmaceutical products must undergo batch testing to verify their quality and compliance with Italian and EU standards. Stability requirements ensure that medicines maintain their efficacy and safety throughout their shelf life. Labeling must be in Italian, providing clear information on dosage, administration, and potential side effects. Serialization mandates are in place to prevent counterfeit products and ensure traceability within the supply chain. (aifa.gov.it)

Between 2024 and 2026, Italy has implemented several policy changes affecting the importation of pharmaceutical products, particularly in response to global supply chain challenges and the need for increased self-sufficiency. These changes include stricter enforcement of GMP compliance, enhanced scrutiny of import licensing applications, and the promotion of parallel imports to mitigate shortages. Pharmaceutical companies, including Accord Healthcare Italia Srl, must stay informed about these regulatory developments to ensure continued compliance and uninterrupted market access. (aifa.gov.it)

Accord Healthcare Italia Srl's product strategy focuses on therapeutic areas with high unmet needs, such as oncology, immunology, and cardiovascular health. The company's importation of specific products like Irinotecan, Fulvestrant, Cytarabine, Cabazitaxel, and Fludarabine aligns with market demand for effective treatments in these areas. By concentrating on these therapeutic categories, Accord Healthcare Italia Srl addresses critical healthcare challenges in Italy, providing patients with access to essential generic medicines.

Accord Healthcare Italia Srl's sourcing strategy emphasizes the procurement of generic drugs, particularly in the oncology and immunology sectors. The company's preference for finished pharmaceutical formulations, as opposed to raw active pharmaceutical ingredients (APIs), reflects a focus on ready-to-market products that meet Italian regulatory standards. India's robust pharmaceutical manufacturing capabilities and adherence to international GMP standards make it a key supplier for Accord Healthcare Italia Srl's procurement needs.

Accord Healthcare Italia Srl serves multiple segments of the Italian pharmaceutical market, including public and private hospital groups, wholesalers, and potentially the retail sector. The company's extensive portfolio of generic medicines positions it as a versatile supplier capable of meeting diverse healthcare needs across various market segments. Its focus on high-demand therapeutic areas further strengthens its market presence and appeal to a broad customer base.

There is a realistic opportunity for new Indian suppliers to collaborate with Accord Healthcare Italia Srl, particularly if they can offer a diverse range of high-quality generic medicines that align with the company's therapeutic focus areas. Gaps in Accord Healthcare Italia Srl's current sourcing may include specific formulations or dosage forms not currently imported from India. By identifying and addressing these gaps, Indian exporters can enhance their competitiveness and appeal to Accord Healthcare Italia Srl.

Indian exporters seeking to supply Accord Healthcare Italia Srl must ensure that their products comply with EU GMP standards and possess the necessary marketing authorizations. Quality certifications, such as WHO GMP or PIC/S, are essential to meet regulatory requirements. Additionally, products must adhere to Italian labeling and serialization mandates to facilitate market entry and distribution.

To establish a partnership with Accord Healthcare Italia Srl, Indian exporters should initiate contact by providing detailed product dossiers that demonstrate compliance with EU GMP standards and Italian regulatory requirements. Participating in relevant tenders and industry events can enhance visibility and facilitate networking opportunities. A clear regulatory filing strategy, including timelines for obtaining necessary approvals, will be crucial for successful collaboration.